Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revvity, Inc. (NYSE: RVTY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Revvity, a Massachusetts-incorporated health science and diagnostics company and member of the S&P 500 index, uses these filings to report material events, financial results, and governance changes related to its operations and securities.
Recent Form 8-K filings illustrate how Revvity communicates with the market. The company files 8-Ks to furnish earnings press releases for its quarterly results, to announce preliminary expectations for financial performance, and to provide presentation materials for major investor conferences such as the J.P. Morgan Healthcare Conference. Other 8-Ks disclose board and executive appointments and confirm details about its registered securities, including common stock and notes listed on the New York Stock Exchange.
Through its filings and accompanying earnings materials, Revvity explains the use of non-GAAP financial measures such as adjusted earnings per share, adjusted operating income, and organic revenue growth. The company describes how management uses these measures to evaluate operating performance, benchmark results, and inform compensation decisions, while also outlining the limitations of non-GAAP metrics and providing reconciliations to GAAP figures.
On this page, Stock Titan surfaces Revvity’s SEC filings with real-time updates from EDGAR and AI-powered summaries that clarify the purpose and implications of each document. Users can quickly understand the key points of quarterly results, changes in guidance, capital allocation actions, and governance updates without reading every line of the original filings. Access to these filings, including Form 8-Ks and related exhibits, helps investors, analysts, and researchers track how Revvity reports its financial condition, segment performance, and significant corporate events over time.
Revvity Inc Schedule 13G/A amendment discloses that The Vanguard Group reports 0 shares beneficially owned of Revvity common stock, representing 0% of the class. The filing explains this follows an internal realignment and reliance on SEC Release No. 34-39538 (January 12, 1998), with certain Vanguard subsidiaries reporting separately.
REVVITY, INC. reported that officer Anita Gonzales received new equity awards as part of her compensation. She was granted a non-qualified stock option for 4,576 shares of common stock at an exercise price of $86.635 per share, expiring on March 16, 2033, which is scheduled to fully vest on the second anniversary of the grant date.
She also received 1,600 time-based restricted stock units that are scheduled to fully vest on the second anniversary of the grant date. After this award, her direct common stock holdings total 7,399 shares. These are grants and awards, not open-market purchases.
Revvity, Inc. is asking shareholders to vote at its 2026 annual meeting, which will be held virtually via live webcast on April 28, 2026 at 8:00 a.m. Eastern Time. Shareholders of record at the close of business on March 2, 2026, when 111,803,327 common shares were outstanding and entitled to vote, may participate and vote online using a control number.
The agenda includes electing ten directors for one-year terms, ratifying Deloitte & Touche LLP as independent registered public accounting firm for fiscal 2026, a non-binding advisory vote on executive compensation, an amendment to the By-laws to allow shareholders owning 25% of stock to call a special meeting, and a shareholder proposal on executive stock ownership. The board recommends voting FOR Proposals 1–4 and AGAINST Proposal 5.
The board has ten members, nine of whom are independent, with an independent non-executive chair and fully independent audit, compensation and nominating committees. In 2025, Deloitte & Touche LLP received total fees of $5,620,000, and non-employee directors generally received a $90,000 cash retainer plus stock and RSU awards targeted at $225,000 in aggregate value, with higher amounts for the chair and committee leaders.
REVVITY, INC. officer Anita Gonzales reported equity compensation awards. On March 6, 2026, she received a grant of 1,616 nonqualified stock options for common stock at an exercise price of $93.07 per share, expiring on March 6, 2033.
On the same date she was also awarded 1,721 time-based restricted stock units, increasing her direct common stock holdings to 5,799 shares after the award. Both the options and RSUs are scheduled to vest in three equal installments on February 15, 2027, February 15, 2028, and February 15, 2029. These are compensation-related grants, not open-market purchases or sales.
Revvity, Inc. will hold its 2026 annual meeting virtually on April 28, 2026 with a record date of March 2, 2026. The board asks shareholders to elect ten directors for one-year terms and to vote on four additional proposals, including ratification of Deloitte & Touche LLP as auditor and a bylaw amendment to permit shareholders owning 25% to call a special meeting.
The company reported 111,803,327 shares outstanding as of the record date. The board recommends FOR Proposals 1–4 and AGAINST the shareholder proposal on executive stock ownership (Proposal 5). Director compensation and annual equity grants for non-employee directors are described, and institutional holders and beneficial ownership schedules are included.
Revvity, Inc. executive Victor Miriame reported option exercises and related share sales. On February 24, 2026, he exercised a nonqualified stock option for 1,862 shares of common stock through a derivative exercise at an exercise price of $0.00 per share.
He simultaneously acquired 1,862 shares of Revvity common stock at $95.74 per share through this option exercise and then sold 1,862 shares in an open-market transaction at $97.13 per share. After these transactions, he directly owned 18,122 shares of common stock. The sales were made under a Rule 10b5-1 trading plan adopted on November 26, 2025.
REVVITY, INC. director Michelle McMurry-Heath sold 600 shares of common stock in an open-market transaction. The weighted average sale price was $97.26 per share, with individual trades between $97.15 and $97.35. After this sale, she directly holds 4,233 shares.
Revvity, Inc. files its annual report describing a global health science business focused on Life Sciences and Diagnostics. The company provides reagents, instruments, software and services that support drug discovery, genomics, imaging and diagnostic testing, marketing products in more than 160 countries.
Revvity reports approximately 11,000 employees as of December 28, 2025 and around 2,000 sales and service representatives across about 40 countries. Its strategy emphasizes innovation, AI-enabled solutions, strategic acquisitions, disciplined capital allocation and operational excellence, while highlighting extensive regulatory, economic, supply chain, technology, environmental, data privacy and debt‑related risks.